From the Journals

Cenobamate Shows Stronger Real-World Seizure Control

Large retrospective analysis highlights differences in seizure control, retention, and adverse effects among newer agents

Share

  • 1

    CREW study compared cenobamate with brivaracetam, lacosamide, and perampanel.

  • 2

    Cenobamate showed significantly higher seizure response rates at 6 and 12 months.

  • 3

    Adverse effects included somnolence and dizziness, but retention was high.

  • 4

    Lacosamide had the best tolerability profile.

  • 5

    Study results help inform empirical treatment choices for drug-resistant epilepsy.

  • 6

    Further prospective studies are recommended for clearer treatment guidance.

Original Source(s)

Cenobamate Shows Stronger Real-World Seizure Control

Large retrospective analysis highlights differences in seizure control, retention, and adverse effects among newer agents

  • by Henry Thomas

  • March 4, 2026

  • 2 min

Related Content

Epilepsy Linked to Heart Risks in Seniors

Brain Cell Networks Mapped with CRISPR

A new Perturb-seq platform utilizes adeno-associated viruses vectors and transposons to examine cell-specific transcriptional networks within the developing brain in vivo.

New Score Assesses Epilepsy Risk Post-CVT

With DIAS3 predicting epilepsy risk post-CVT from as low as 7% to 83% over three years, doctors can tailor ASM strategies based on a patient’s individual profile—advancing precision in CVT care.